secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAPTYSBIO, INC (ANAB)
CIK:        0001370053
Form:       8-K
Filed at:   2025-11-21T23:59:59+00:00
Accession:  0001370053-25-000096
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

AnaptysBio sues Tesaro and GSK for breach of Jemperli collaboration; countersuit filed
--------------------------------------------------------------------------------

- AnaptysBio alleges Tesaro breached exclusivity by conducting trials with competing PD-1 antagonists (e.g., Keytruda) and failing to maximize Jemperli return.
- Tesaro countersued AnaptysBio on Nov 20, 2025, seeking injunctive relief; AnaptysBio calls claims meritless and will seek dismissal.
- Parties agreed to expedited Delaware Chancery Court schedule; trial anticipated July 2026.
- Milestone and royalty payments under Collaboration Agreement remain due during litigation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1370053/000137005325000096/0001370053-25-000096-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1370053/000137005325000096/anab-20251120.htm
  HTML page:      https://secwatch.observer/filing/0001370053-25-000096

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer